Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

NYAB Oyj - Managers' Transactions

NYAB PlcMANAGERS' TRANSACTIONS25 June 2024 at 09:30 NYAB Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Holding Investment Förvaltning i Luleå ABPosition: Closely associated person(X) Legal person (1):Person Discharging Managerial Responsibilities In IssuerName: Johan LarssonPosition: Chief Executive Officer(2):Person Discharging Managerial Responsibilities In IssuerName: Mikael RitolaPosition: Other senior managerIssuer: NYAB OyjLEI: 743700UX7WTIOT3QO547Notification type:

ArcticZymes Technologies Announces Nomination of Dr. Frank Mathias as Chairman of the Board

Tromsø, Norway – June 25, 2024 – ArcticZymes Technologies (OSE:AZT) is pleased to announce the nomination of Dr. Frank Mathias as the new Chairman of the Board.Dr. Mathias is the CEO at Oxford Biomedica, a leading pure-play CDMO within the cell and gene therapy industry. Dr. Mathias was previously the CEO of Rentschler Biopharma SE, which he successfully developed into a leading global, full-service CDMO. Prior to Rentschler, Dr. Mathias served as CEO of Medigene AG, a publicly listed immuno-oncology company. During his 30-year career, Dr. Mathias has held senior roles at leading global

Update on Imfinzi ADJUVANT BR.31 trial

25 June 2024 Update on ADJUVANT BR.31 Phase III trialof Imfinzi in non-small cell lung cancer High-level results from the ADJUVANT BR.31 Phase III trial, sponsored by the Canadian Cancer Trials Group (CCTG), showed Imfinzi (durvalumab) did not achieve statistical significance for the primary endpoint of disease-free survival (DFS) versus placebo in early-stage (IB-IIIA) non-small cell lung cancer (NSCLC) after complete tumour resection in patients whose tumours express PD-L1 on 25% or more tumour cells.  Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: "

Notice of AGM

25 June 2024 Evrima plc (“Evrima” or the “Company”) Notice of Annual General Meeting   Evrima (AQSE: EVA) is pleased to announce that's its Annual General Meeting "AGM") will be held at Warnford Court, 29 Throgmorton Street, London, EC2N 2AT on Friday 19 July 2024 at 3 p.m. The AGM notice has been posted to Shareholders today and will shortly be available on the Company's website at https://evrimaplc.com/. The Directors of Evrima accept responsibility for this announcement.   Enquiries:  Company: Burns Singh Tennent-Bhohi (CEO & Director): burns@evrimaplc.com

£2.6 million investment into LoopFX

25 June 2024   Augmentum Fintech plc   £2.6 million investment into LoopFX     Augmentum Fintech plc (LSE: AUGM) (the "Company" or "Augmentum"), Europe's leading publicly listed fintech fund, announces that it has made a £2.6 million investment into London based LoopFX.   LoopFX (www.theloopfx.com) is the new independent venue for large spot FX trades with a unique matching solution for market participants. LoopFX enables traders to match, in real-time, with other asset managers and banks without information leakage and at a mid-market rate, reducing trading costs

Repurchases of shares during week 25, 2024

Between 17 June and 20 June 2024 Attendo AB (LEI code 549300KEJDL2FNITUW65) (“Attendo”) has repurchased in total 120,635 own shares (ISIN: SE0007666110) as part of the repurchase program initiated by the Board.The repurchases form part of the repurchase program of a maximum of 16,138,659 own shares for a total maximum amount of SEK 110,000,000 that Attendo announced on 24 April 2024. The repurchase program, which runs between 29 April 2024 and 18 July 2024, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 and the Commission Delegated Regulation (EU) No

Housing: The Most Critical Future Issue for Youth – Yet Many Feel Anxiety and Stress

- Owning a nice home tops the wish list over exploring the world or starting a family Nearly 9 out of 10 young people consider having a nice home in the future as important. Meanwhile, 6 out of 10 find the housing situation in Sweden to be entirely unreasonable and believe that their personal finances and mental health would be affected if they struggle to secure housing in the future. These are some of the insights from a new survey by Ungdomsbarometern, conducted on behalf of Mäklarsamfundet and Hemnet, presented during Almedalsveckan.  “Youth dream strongly of owning their own home,

Imfinzi improved EFS and OS in bladder cancer

25 June 2024 Imfinzi demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial First immunotherapy regimen before and aftersurgery to extend survival in bladder cancer Positive high-level results from the NIAGARA Phase III trial showed AstraZeneca's Imfinzi(durvalumab) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (EFS) and the key secondary

Augmentum Fintech plc Annual Report 2024

25 June 2024 Augmentum Fintech plc Annual Financial Report for the year ended 31 March 2024     Augmentum Fintech plc (LSE: AUGM) (the "Company" or "Augmentum"), Europe's leading publicly listed fintech fund, announces its audited Annual Results for the year ended 31 March 2024.  Financial highlights   · NAV before performance fee increased by 3.1% to £303.3 million1 (31 March 2023: £294.1 million1) of which the value of the investment portfolio was £265.1 million (31 March 2023: £254.3 million). · NAV per share after performance fee increased by 5.4% to 167.4p2

Wärtsilä renews its partnership with ONEE for the maintenance of two power plants in Morocco

Wärtsilä Corporation, Trade press release, 25 June 2024 at 9 AM EESTTechnology group Wärtsilä has signed a five-year Maintenance Agreement covering 169,5 MW of power generation for two Moroccan power plants. The plants are owned and operated by the Office National de l’Electricité et de l’Eau potable (ONEE), Morocco‘s public utility in charge of the production, transport and distribution of electricity. This agreement is a renewal of a previous five-year contract for the power plants in Tan Tan and Dakhla, in southern Morocco. Each of these two emergency plants operates with Wärtsilä 46

ASSA ABLOY acquires Wesko Locks in Canada

ASSA ABLOY has acquired Wesko Locks Ltd, a Canadian manufacturer and supplier of electronic and specialty locks. "I am very pleased to welcome Wesko Locks into the ASSA ABLOY Group. This acquisition delivers on our strategy to strengthen our position in mature markets through adding complementary products and solutions to our core business,” says Nico Delvaux, President and CEO of ASSA ABLOY. "Wesko Locks has an extensive portfolio that complements our current high-security products and solutions,” says Lucas Boselli, Executive Vice President of ASSA ABLOY and Head of the Americas

Stayble Therapeutics presents positive interim data from the ongoing phase Ib study with STA363

Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the Company's phase Ib study has reached the follow-up goal of at least 18 patients completing their three-month visit. A total of 24 patients completed the visit. All essential data for evaluating the study's primary parameters have thus been secured. The company also presents positive interim data with established safety and tolerability (primary study objective) when evaluating available blinded data from the three-month follow-up. The patients will be followed until they complete their six-month visit. Then, the

Lundbeck and Otsuka announce FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD)

· The supplemental new drug application (sNDA) for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD) has been accepted and filed by the FDA · The FDA target date (PDUFA date) for completion of the review is 8 February 2025 · If approved, brexpiprazole and sertraline combination treatment would be the first FDA-approved pharmacological treatment for PTSD in more than 20 years  Valby, Denmark, 25 June 2024 – H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announce the U.S. Food and Drug

Observe Medical ASA: Ex. Subsequent Offering today

OBSRV – EX. SUBSEQUENT OFFERING TODAY Issuer name: Observe Medical ASA Ex. date: 25 June 2024 Type of corporate action: Subsequent offering/repair issue Additional information: Reference is made to the stock exchange announcement published by Observe Medical ASA on 24 June 2024 with key information relating to the subsequent offering.   This information is published in accordance with the requirements of the Continuing Obligations.

Instabee adds 4,000 square metres with Wihlborgs in Helsingborg

The logistics company Instabee has signed an agreement for an additional 4,000 square metres at the Rubinen 8 property in the Ättekulla industrial area in Helsingborg.Instabee, which includes the consumer brands Budbee and Instabox, offers deliveries either to consumers’ homes or to a parcel locker. Instabee operates in six countries and can be selected as a shipping alternative with the majority of the major online retailers in Sweden. Instabee has been a tenant of Wihlborgs since 2018, when it leased 220 square metres at Berga. Since 2021, the company has been leasing 2,000 square

Neogap granted Chinese patent for innovative method of MS treatment and diagnosis

Neogap Therapeutics, a Swedish biotechnology company specialising in the development of personalised immunotherapy, has been granted a patent in China for an innovative method that opens new possibilities in the treatment and diagnosis of multiple sclerosis (MS). The patent, which complements a previously granted patent in Australia, strengthens Neogap's global presence in the field, the company's strategic intellectual property portfolio, and its ongoing research into autoimmune diseases such as MS.The patent covers a tolerogenic treatment method for multiple sclerosis (MS) using specially

Skanska signs contract with MARTA in Georgia, USA, worth USD 49M, about SEK 500M

Skanska has signed an initial contract with MARTA, Metropolitan Atlanta Rapid Transit Authority, to deconstruct the MARTA Five Points Station canopy in Atlanta, Georgia. The contract is worth USD 49M, about SEK 500M, which will be included in the second quarter of 2024.The contract includes deconstruction of the existing pre-stressed concrete canopy and demolition of the plaza to make way for a new mass timber, open-concept canopy with new pedestrian entrances. Five Points Station is the largest and busiest rail station in the MARTA system, and the connecting point for all rail lines and

Circio´s leading position in circular RNA therapeutics highlighted by broad recent coverage in international life science industry media

· Circio´s position as a pioneering player in the rapidly emerging circular RNA field is being recognized in the industry · Five articles and interviews have recently been published in widely read EU and US life science publications with a combined readership of over 3 million · Additional high-profile interviews are expected to generate further coverage in the coming monthsOslo, Norway, 25 June 2024 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing next generation circular RNA vector technology for gene therapy, today announces that it has initiated a systematic

Skanska divests courthouse building in Växjö, Sweden for about SEK 490M

Skanska divests a court building in Växjö, where the Swedish Courts Administration is a tenant, for approximately SEK 490M. The transaction will be recorded by Skanska Commercial Development in the second quarter of 2024. Transfer of ownership and payment of the purchase price will take place in connection with the completion of the court, which is planned for the fourth quarter of 2026.The court is developed by Skanska in collaboration with Vacse. The building is being constructed by Skanska Sweden and is included in the order intake for the second quarter, 2024. The investment, including

SINDI: En ny standard för social hållbarhet inom fastighetsbranschen

Stockholm 2024-06-25Brunswick Real Estate (”Brunswick”), Infostat och Ramboll Management Consulting lanserar idag SINDI, Social Index for Improvement – en digitalt plattform som gör det möjligt för fastighetsbolag att mäta, följa upp och jämföra sitt sociala hållbarhetsarbete. Ambitionen med SINDI är att etablera en standard för social hållbarhet inom fastighetsbranschen.SINDI samlar expertis från Brunswick inom fastighetsinvesteringar och social hållbarhet, Infostats avancerade dataanalyser, samt Rambolls omfattande erfarenhet och kompetens inom rådgivning kopplat till social hållbarhet

Blue World completes successful testing of 200 kW maritime fuel cell system to run on green methanol

With a successful test of the first ever 200 kW HT PEM fuel cell system, an important milestone was reached in bringing new technology into play to push forward the decarbonisation of the maritime industry.[200 kW fuel cell system is tested at Blue Worlds test facilities in connection to the fuel cell factory in Aalborg Denmark] 200 kW fuel cell system is tested at Blue World's test facilities in connection to the fuel cell factory in Aalborg, Denmark     Aalborg, Denmark, 25 June 2024 – After months of preparation, Blue World Technologies is proud to announce the successful

Diös divests properties for SEK 452 milllion

Diös divests 10 properties in five cities including housing, light industry, commerce and offices. This is done through three different transactions, which take place in line with the company's strategy. The total leasable area of the divested the properties correspond to approximately 57,000 square meters and the total sales price amounts to SEK 452 MSEK. One of the divested properties, Målaren 3 in Borlänge. The buyers of the properties are NP3 Fastigheter AB, LF Norrbotten and Hagabacken Fastigheters AB. The total rental value corresponds to SEK 53.4 million and the

Gaming Innovation Group - Notification of changes in major shareholdings

MJ Foundation Fundacja Rodzinna, a company related to Mateusz Juroszek, primary insider and Board Member of Gaming Innovation Group Inc. (GiG), has today agreed to purchase 6,069,375 shares in GiG at a price of SEK 27.00 per share on 24.06.2024, ref. also separate announcement regarding mandatory notification of trade today. After the transaction, MJ Foundation holds 11,088,810 shares, representing approximately 8,24% of the total registered share capital and voting rights in GiG.  After the above transaction, Juroszek Family through MJ Foundation, ZJ Foundation, Betplay Capital Sp. z o.

There are no items matching the current filter
There are no more items matching the current filter
Back to top